Diary Prequel Package — page 206

com 35 PM Favor solicits my opinion about the risk of exacerbation of PML associated with immune suppression for prevention of transplant rejection. It might seem presumptuous for me to pre-emptively call them. If Dan's private physician could suggest to them that I would be happy to discuss this issue with them, this would be fine. Then it would be up to them to decide if they are interested in my opinion. My expeerience has been that if you impose yourself on people, they get offended and clearly ignore you. Best regards, Tony Anthony S. Fauci, MD Director National Institute of Allergy and Infectious Diseases Building 31, Room 7A-03 31 Center Drive, MSC 2520 National Institutes of Health Bethesda, MD 20892-2520 Phone: (301) 496-2263 FAX: (301) 496-4409 E-mail: afauci@niaid.nih.gov The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives. From: Zuzu [mailto:zuzu77@gmail.com] Sent: Monday, March 16, 2009 12:35 PM To: Fauci, Anthony (NIH/NIAID) [E] Subject: Favor Tony - case is being heard by the UCSF transplant committee on February 21st. Other than history of PML (diagnosed in early '96, went on potent, high dose combination ARV therapy, quadruple dose saquinavir (early version, not terribly bioavailable), 1200 mg AZT, double dose 3TC and something else, I can't remember - PML went into remission and has remained in remission since then. His CD4+ cell count never dropped below 400) he is eligible for transplantation. He responded well to RFA